Sysmex Inostics Announces the Opening of Its Global Training Center for the OncoBEAM(TM) Platform in Barcelona, Spain

USA Profile Username: jon@newsinnovations.com / edit profile Sysmex Inostics Announces the Opening of Its Global Training Center for the OncoBEAM™ Platform in Barcelona, Spain PR Newswire BARCELONA, Spain, June 28, 2016 BARCELONA, Spain, June 28, 2016 /PRNewswire/ -- Sysmex Inostics, a subsidiary of Sysmex Corporation, today announced the opening of a global OncoBEAM™ Training Center in Barcelona. The new state-of-the-art facility is designed to educate and train customers from all over the world on the Sysmex Inostics OncoBEAM™ technology platform and the recently released OncoBEAM™ RAS CRC test.  The OncoBEAM™ RAS CRC test is the first CE-Mark liquid biopsy assay helping oncologists determine the most effective therapy for patients with metastatic colorectal cancer. "The opening of our Training Center marks an important milestone for us as we now have a dedicated facility for educating and training our customers on the OncoBEAM™ molecular diagnostic assays in oncology," said Fernando Andreu, CEO of Sysmex Inostics. Sysmex Inostics' highly sensitive molecular diagnostic testing solutions allow for genetic analysis of cell-free tumor DNA from blood, delivering an individualized approach to complement treatment decision-making in oncology. Blood based molecular testing allows for new possibilities for cancer management, while minimizing costs and risks inherent with tissue biopsies. Sysmex Inostics' comprehensive OncoBEAM™ RAS CRC test is a simplified method for determining the RAS mutation status of tumors, which requires only a single blood-draw allowing for informed and rapid treatment decisions. The OncoBEAM™ RAS CRC test will be widely implemented across Europe, Asia, Latin America and Australia by the end of 2016. OncoBEAM™ is a trademark of Sysmex Corporation. OncoBEAM™ is distributed and marketed by Sysmex. About Sysmex Inostics  Sysmex Inostics, a subsidiary of Sysmex Corporation, is a molecular diagnostic company whose core competency is mutation detection in blood through highly sensitive molecular methods. Our OncoBEAM™ blood-based tests deliver a minimally invasive alternative for sensitive real time molecular diagnostics to improve cancer characterization and treatment. Sysmex Inostics is a trusted partner to leading pharmaceutical companies, advancing their efforts to bring the most effective personalized cancer therapies to global markets. Sysmex Inostics companion diagnostics (CDx) team offers services for the development of non-invasive cell-free DNA-based IVD tests supported by a growing network of partners to cover the entire IVD development process. Sysmex Inostics' headquarters and Service Laboratory are located in Hamburg, Germany; Sysmex Inostics' Clinical Laboratory is located in Baltimore, Maryland. For more information on OncoBEAM™ blood testing and the BEAMing technology refer to http://www.sysmex-inostics.com or email info@sysmex-inostics.com . Contact: Friederike Lehmann Sysmex Inostics GmbH Phone +49-(0)40-325907-0 Fax   +49-(0)40-325907-6511 lehmann.friederike@sysmex-inostics.com Follow Us To change the settings for your profile(s) or email delivery, go to https://prnmedia.prnewswire.com/profile/?action=editProfile and select the profile you would like to edit. You can select the industries, subjects, languages, geographical areas, companies, delivery options and delivery frequencies of your choice. In addition to current press releases, you can also find archived news, corporate information, photos, tradeshow news and much more on the PR Newswire for Journalists website: https://prnmedia.prnewswire.com To contact us, email: mediasite@prnewswire.com Please do not reply to this email; this is an automatically generated message. Copyright © PR Newswire Association LLC. All Rights Reserved. A UBM plc company. Our mailing address is: 350 Hudson Street, Suite 300 New York, NY 10014-4504